Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-23-015034
Filing Date
2023-08-16
Accepted
2023-08-16 16:10:33
Documents
8
Period of Report
2023-09-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20230928xdef14a.htm DEF 14A 813364
2 GRAPHIC tmb-20230928xdef14a_a001.jpg GRAPHIC 5607
3 GRAPHIC tmb-20230928xdef14a_a002.jpg GRAPHIC 4854
4 GRAPHIC tmb-20230928xdef14a_a003.jpg GRAPHIC 7501
5 GRAPHIC tmb-20230928xdef14a_a009.jpg GRAPHIC 28307
6 GRAPHIC tmb-20230928xdef14a_a010.jpg GRAPHIC 27601
7 GRAPHIC tmb-20230928xdef14a_bg001.jpg GRAPHIC 218878
8 GRAPHIC tmb-20230928xdef14a_bg002.jpg GRAPHIC 170188
  Complete submission text file 0001558370-23-015034.txt   1453275
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-32587 | Film No.: 231178325
SIC: 2834 Pharmaceutical Preparations